Translating Structural Biology & Medicinal Chemistry into the Clinic: Modulating Integrin Pathways with Confidence & Validating Preclinical Hypothesis in Clinical Settings

Welcome to the 2nd Integrin-Targeted Drug Development Summit

The Only Industry-Led Event Dedicated to Uncovering the Therapeutic Potential of Integrins

Over the last 12 months, the industry has witnessed promising data and candidates entering the clinic. 7 Hills PharmaCorbus Pharmaceuticals, Vincerx, and Morphic are paving the way to develop a safe, efficacious integrins-targeted drug to modify disease biology, which will be a game-changer for diseases such as oncology, autoimmune, and ophthalmology, with unmet medical needs.

In collaboration with leading integrin drug developers, including Genentech, 7 Hills Pharma, and Pfizer, the 2nd Integrin-Targeted Drug Development Summit is designed for industry leaders to unite and outline clinical strategies for success, including patient selection biomarkers and dosing.

Get your critical questions answered to supercharge your clinical programs, direct your drug pipelines and ensure you take lessons learned to successfully modulate integrins to improve treatment regimens in chronic, familiar, and rare diseases. 

Join us for this 3-day summit to gain unparalleled insights and experience first-hand from integrin drug developers to accelerate your candidate into the clinic and develop a first-in-class treatment option by modifying underlying disease biology for our patients.

Snapshot of World-Class Speaker Faculty:

Previously Attending Companies Include:

“This conference expanded my general knowledge of TGFB biology and was a great platform to learn about new therapies and current therapeutic challenges.”

Past Portfolio Attendee,
Researcher,
EMD Serono

Gained insights on direction of the field with regards to modalities in targeting the TGFb pathway”

Past Portfolio Attendee,
Senior Scientist,
AbbVie

“Very good experience. I learned so much.”


Past Portfolio Attendee,
Senior Director – Immunology,
Bicara Therapeutics